Odds ratio for MRI outcomes for each 10 µmol/L increase in alpha-tocopherol.

a<p>587 alpha-tocopherol/MRI pairs,</p>b<p>254 alpha-tocopherol/MRI pairs,</p>c<p>333 alpha-tocopherol/MRI pairs.</p

Odds ratio for lagged MRI outcomes for each 10 µmol/L increase in alpha-tocopherol.

a<p>Whole study period: Lag 1∶88 patients, 419 observations, Lag 2∶88 patients, 420 observations.</p>b<p>Prior to IFNB: Lag 1∶88 patients, 250 observations, Lag 2∶88 patients, 251 observations.</p>c<p>During IFNB: Lag 1∶86 patients, 169 observations, Lag 2∶87 patients, 169 observations.</p

Seasonal distribution of alpha-tocopherol concentrations in serum during the whole study period.

<p>All 780 alpha-tocopherol measurements from 88 patients clustered to the calendar month of sampling. Error bars represent SD.</p

MRI activity and mean concentrations (positive SD) of inflammation markers significantly associated with MRI outcomes throughout the study.

<p>All available observations at each time point are included (see Table S1 for numbers). All T1Gd⁺ lesions are shown at month 0 (baseline). Abbreviations: CXCL16: Chemokine (C-X-C motif) ligand 16, OPG: osteoprotegerin, MMP-9: matrix metalloproteinase 9, T1Gd⁺: gadolinium enhancing T1 MRI lesion, CUA: combined unique activity.</p

Conditional analyses of the HLA-A, -B, -C and DRB1 loci (p-values) in early onset myasthenia gravis (EOMG).

<p>P-values are not corrected, p<0.01 is considered significant after correction for multiple comparisons (n = 4).</p

Schematic overview of associated HLA alleles in MG.

<p>The HLA complex on chromosome 6 with its division into three classes. Some key genes and their order on the chromosome are given. Associated HLA alleles reported earlier in Caucasian MG patients (see text for complete references) are illustrated together with the results from the present study.</p

Clinical characteristics of the Norwegian myasthenia gravis study cohort (n = 369).

1<p>According to MGFA classification <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0036603#pone.0036603-JaretzkiA1" target="_blank">[39]</a>: ocular MG (MGFA grade I), generalised MG (MGFA grade II-V), not available in 12 cases.</p>2<p>Concomitant immune-mediated diseases include thyroid disease (hypo-, hyperthyroidsm, thyroiditis), type 1-diabetes, rheumatic diseases, systemic lupus erythematosus (SLE), celiac disease, inflammatory bowel diseases (Crohńs disease or ulcerative colitits). EOMG = early onset MG; LOMG = late onset MG; AChR-ab+  =  acetylcholine receptor-antibody positive.</p

Assessment of the strongest association on the HLA-B*08-DRB1*03:01 haplotype in early onset myasthenia gravis (EOMG).

<p>+  =  positives, −  =  negatives.</p

The association between HLA loci and myasthenia gravis subgroups (p-values).

<p>EOMG = early onset MG, LOMG = late onset MG.</p><p>P-values are not corrected, p<0.01 is considered significant after correction for multiple comparisons (n = 4).</p

Associated alleles in late onset myasthenia gravis (LOMG).

<p>Odds Ratio (OR) and 95% confidence interval (CI) are shown for nominal p-values.</p